ARTV
Artiva Biotherapeutics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$382.39M
P/E Ratio
—
EPS
$-3.55
Beta
—
52W High
$14.53
52W Low
$1.47
50-Day MA
$8.59
200-Day MA
$5.03
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Artiva Biotherapeutics, Inc. Common Stock
Artiva Biotherapeutics, Inc. is a pioneering biotechnology firm focused on developing next-generation cell therapies specifically targeting cancer, leveraging its proprietary platform to enhance natural killer (NK) cell therapies. With a diverse pipeline aimed at various hematologic and solid tumors, Artiva demonstrates a strong commitment to innovation within the immuno-oncology sector. The company emphasizes scientific rigor and has established strategic collaborations, positioning it favorably to make significant strides in cancer treatment and improve patient outcomes as its promising therapeutic candidates advance through clinical trials.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-89.43M |
| Operating Margin | 0.00% |
| Return on Equity | -67.90% |
| Return on Assets | -38.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.55 |
| Price-to-Book | 4.35 |
| Price-to-Sales (TTM) | 8.11 |
| EV/Revenue | 7.54 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $48.59M |
| Float | $6.00M |
| % Insiders | 11.19% |
| % Institutions | 48.16% |
Historical Volatility
HV 10-Day
66.20%
HV 20-Day
132.88%
HV 30-Day
157.13%
HV 60-Day
133.37%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($35.80 target)
1
Strong Buy5
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026